Loss of Heterozygosity of Tumor Suppressor Genes (p16,Rb,E-cadherin,p53) in Hypopharynx Squamous Cell Carcinoma

Abstract

Objective. Microsatellite alterations, especially those that cause loss of heterozygosity (LOH), have recently been postulated as a novel mechanism of carcinogenesis and a useful prognostic factor in many kinds of malignant tumors. However, few studies have focused on a specific site, hypopharynx. The aim of this study was to evaluate the relationship between LOH and hypopharyngeal squamous cell carcinoma (HPSCC).

Study Design. Laboratory-based study.

Setting. Integrated health care system.

Subjects and Methods. Matched normal and cancerous tissues from 30 patients with HPSCC were examined for LOH in 4 tumor suppressor genes (TSGs) (p16, Rb, E-cadherin, and p53) at loci 9p21, 13q21, 6q22, and 17p13, respectively, using microsatellite markers amplified by polymerase chain reaction. The results for each loci were compared with clinicopathological features.

Results. Among the 30 cases, 26 (86.7%) exhibited LOH, with the most common alteration being LOH at p53 (52.6%). Significantly higher rates of LOH detection were seen in Rb, p53, and the LOH-high group (cases where 2 or more loci with LOH were found) in cases of lymph node metastasis. Compared with stage I and II carcinoma, tumors of stages III and IV had significantly higher frequencies of LOH in Rb, p53, and the LOH-high group. However, the presence of LOH was not significantly correlated with survival.

Conclusion. These results suggest that LOH in TSGs such as Rb and p53 may contribute to the development and progression of HPSCC. The presence of LOH in the primary tumor may also be predictive of lymph node metastasis.

Keywords

hypopharynx squamous cell carcinoma tumor suppressor genes loss of heterozygosity p16 Rb E-cadherin p53

Get full access to this article

View all access options for this article.

References

Rodrigo

González

Lazo

. Genetic alterations in squamous cell carcinomas of the hypopharynx with correlations to clinicopathological features. Oral Oncol. 2002;38:357-363.

Eckel

Staar

Volling

. Surgical treatment for hypopharynx carcinoma: feasibility, mortality, and results. Otol Head Neck Surg. 2001;124:561-569.

Seiwart

Salama

Vokes

. The chemoradiation paradigm in head and neck cancer. Nat Clin Pract Oncol. 2007;4:156-171.

Scholnick

Sun

Shaw

. Frequent loss of heterozygosity for Rb, TP53, and chromosome arm 3p, but not NME1 in squamous cell carcinomas of the supraglottic larynx. Cancer. 1994;15:73:2472-2480.

Gold

Kim

. Role of molecular markers and gene profiling in head and neck cancers. Curr Opin Oncol. 2009;21:206-211.

Vokes

Weichselbaum

Lippman

. Head and neck cancer. N Engl J Med. 1993;328:184-194.

Boyle

Hakim

Koch

. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res. 1993;53:4477-4480.

Rodrigo

Suárez

González

. Variability of genetic alterations in different sites of head and neck cancer. Laryngoscope. 2001;111:1297-1301.

Miracca

Yamamoto

Contado

. Distinct chromosomal deleted regions defining different subsets of head and neck tumors. Diagn Mol Pathol. 2001;9:229-233.

10.

Shiga

Matsuura

Tateda

. Allelic loss correlated with tissue specificity in head and neck squamous cell carcinomas and the clinical features of patients. Tohoku J Exp Med. 2004;204:163-172.

11.

Gonzalez

Pello

Lopez-Larrea

. Loss of heterozygosity and mutation analysis of the p16 (9p21) and p53 (17p13) genes in squamous cell carcinoma of the head and neck. Clin Cancer Res. 1995;1:1043-1049.

12.

Edge

Compton

. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471-1474.

13.

Blons

Cabelguenne

Carnot

. Microsatellite analysis and response to chemotherapy in head-and-neck squamous-cell carcinoma. Int J Cancer. 1999;84:410-415.

14.

Fiedler

Hoppe

Schimmel

. Molecular characterization of head and neck tumors by analysis of telomerase activity and a panel of microsatellite markers. Int J Mol Med. 2002;9:417-423.

15.

Glavac

Volavsek

Potocnik

Ravnik-Glavac

Gale

. Low microsatellite instability and high loss of heterozygosity rates indicate dominant role of the suppressor pathway in squamous cell carcinoma of head and neck and loss of heterozygosity of 11q14.3 correlates with tumor grade. Cancer Genet Cytogenet. 2003;146:27-32.

16.

Lee

. Allelic loss at chromosomes 3p, 8p, 13q, and 17p associated with poor prognosis in head and neck cancer. J Natl Cancer Inst. 1994;86:1524-1529.

17.

Weinberger

Haffty

. Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J Clin Oncol. 2006;24:736-747.

18.

Marsit

Black

Posner

. A genotype-phenotype examination of cyclin D1 on risk and outcome of squamous cell carcinoma of the head and neck. Clin Cancer Res. 2008;14:2371-2377.

19.

Namazie

Alavi

Olopade

. Cyclin D1 amplification and p16(MTS1/CKD4I) deletion correlate with poor prognosis in head and neck tumors. Laryngoscope. 2002;112:472-481.

20.

Pećina-Slaus

Kljaić

Nikuseva-Martić

. Loss of heterozygosity of APC and CDH1 genes in laryngeal squamous cell carcinoma. Pathol Res Pract. 2005;201:557-563.

21.

Franchi

Gallo

Boddi

. Prediction of occult neck metastases in laryngeal carcinoma: role of proliferating cell nuclear antigen, MIB-1, and E-cadherin immunohistochemiacal determination. Clin Cancer Res. 1996;2:1801-1808.

22.

Takes

Baatenburg de Jong

Ales

MJRC

. Markers for nodal metastasis in head and neck squamous cell cancer. Arch Otolaryngol Head Neck Surg. 2002;128:512-518.

23.

Bowie

Caslin

Roland

Field

JKM

Jones

Kinsella

. Expression of the cell-cell adhesion molecule E-cadherin in squamous cell carcinoma of the head and neck. Clin Otolaryngol Allied Sci. 1993;18:196-201.

24.

Kurtz

Hoffman

Zimmerman

Robinson

. Decreased E-cadherin but not beta-catenin expression is associated with vascular invasion and decreased survival in head and neck squamous carcinomas. Otolaryngol Head Neck Surg. 2006;134:142-146.

25.

Pietruszewska

Klatka

Borzecki

. Loss of heterozygosity for Rb locus and pRb immunostaining in laryngeal cancer: a clinicopathologic, molecular and immunohistochemical study. Folia Histochem Cytobiol. 2008;46:479-485.

26.

Rafferty

Walker

Husband

. Retinoblastoma gene abnormalities in early laryngeal cancer. Eur Arch Otorhinolaryngol. 2008;265(suppl 1):S83-S87.

27.

Shibagaki

Shimada

Wagata

. Allelotype analysis of esophageal squamous cell carcinoma. Cancer Res. 1994;54:2996-3000.

28.

Weber

Zhang

. Microenvironmental genomic alterations and clinicopathological behavior in head and neck squamous cell carcinoma. JAMA. 2007;297:187-195.

29.

Takes

Baatenburg de Jong

Schuuring

. Differences in expression of oncogenes and tumor suppressor genes in different sites of head and neck squamous cell. Anticancer Res. 1998;18:4793-4800.

30.

Xiao

Lam

Yuen

. Microsatellite alterations in squamous cell carcinoma of the head and neck: clustering of loss of heterozygosity in a distinct subset. Oral Oncol. 2000;36:484-490.

31.

Choi

Roberts

Johnigan

. Molecular and clinicopathologic comparisons of head and neck squamous carcinoma variants: common and distinctive features of biological significance. Am J Surg Pathol. 2004;28:1299-1310.

32.

El Naggar

Hurr

Batsakis

Luna

Goepfert

Huff

. Sequential loss of heterozygosity at microsatellite motifs in preinvasive and invasive head and neck squamous carcinoma. Cancer Res. 1995;55:2656-2659.

33.

Ogawara

Miyakawa

Shiba

. Allelic loss of chromosome 13q14.3 in human oral cancer: correlation with lymph node metastasis. Int J Cancer. 1998;79:312-317.

34.

Partridge

Emilion

Langdon

. LOH at 3p correlates with a poor survival in oral squamous cell carcinoma. Br J Cancer. 1996;73:366-371.

35.

Ernoux-Neufcoeur

Arafa

Decaestecker

. Combined analysis of HPV DNA, p16, p21 and p53 to predict prognosis in patients with stage IV hypopharyngeal carcinoma. J Cancer Res Clin Oncol. 2011;137:173-181.

36.

Hara

Smith

Parry

. Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence. Mol Cell Biol. 1996;16:859-867.

37.

Paik

Shak

Tang

. Multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817-2826.